Ten Things You Might Not Know about Iron Oxide Nanoparticles

• Published in: Radiology Vol. 284; no. 3; pp. 616 - 629
• Main Author: Daldrup-Link, Heike E.
• Format: Journal Article
• Language: English
• Published: United States Radiological Society of North America 01.09.2017
• Subjects: Abdomen - diagnostic imaging; Animals; Brain - diagnostic imaging; Clinical Trials, Phase III as Topic; Contrast Media - administration & dosage; Contrast Media - adverse effects; Contrast Media - therapeutic use; Drug-Related Side Effects and Adverse Reactions - prevention & control; Gadolinium - therapeutic use; Humans; Magnetic Resonance Imaging - methods; Magnetite Nanoparticles - administration & dosage; Magnetite Nanoparticles - adverse effects; Magnetite Nanoparticles - therapeutic use; Rats; Reviews and
• ISSN: 0033-8419; 1527-1315; 1527-1315
• DOI: 10.1148/radiol.2017162759

Amid mounting concerns about nephrogenic sclerosis and gadolinium deposition in the brain, physicians and patients alike are starting to question the use of gadolinium chelates for clinical magnetic resonance (MR) imaging. The search for safer alternatives is currently underway. In North America, the iron supplement ferumoxytol has gained considerable interest as an MR contrast agent. In Europe, ferumoxtran-10 is entering phase III clinical trials. As these agents are starting to be used by a new generation of radiologists, important clinical questions have re-emerged, including those that have been answered in the past. This article offers 10 important insights for the use of iron oxide nanoparticles in clinical MR imaging.